-
Mashup Score: 20
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved
Source: www.businesswire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 51
KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS). At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery (neoadjuvant), followed by resection and KEYTRUDA as a single agent after surgery (adjuvant), demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously
Source: www.merck.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!! -NSCLC Stage II, IIIA or IIIB (T3-4N2) -Pembrolizumab is the first PD1 drug with OS in a perioperative setting! -Initially presented at #ASCO23 -Update at #ESMO23 https://t.co/rvGAQCu1yI @OncoAlert @myESMO @OncBrothers https://t.co/unbjYU8Atv https://t.co/vGyoOx3Oh4
-
🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 https://t.co/gJtIzuB4xV https://t.co/CPDSHjQwOg
-
-
Mashup Score: 2Neoadjuvant Chemo: Insights & Its Role in Cancer Care - 8 month(s) ago
In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of cancer. When diagnosed with cancer, patients are presented with a spectrum of treatment modalities, and one of the most crucial decisions revolves around when and how to administer chemotherapy. Am…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer - 10 month(s) ago
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Neoadjuvant Chemoradiation for Treatment of LARC - 10 month(s) ago
Interview with David Henry MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
A pooled analysis of neoadjuvant immunotherapy trials in melanoma shows that the degree of pathological response associates with patient survival and might represent a surrogate marker for long-term outcomes.
Source: NatureCategories: Latest Headlines, Oncologists2Tweet-
So proud! BUT we have more work to do! Major pathological response only 30% with anti- PD-1 alone as used in SWOG1801 and >70% with #neoadjuvant anti-PD1 + CTLA as used in ongoing NADINA study #NCT04949113 in #melanoma (@MelanomaAus sponsor in Australian ) https://t.co/RkOyCT8VLQ https://t.co/aDfmEy4j6j
-
-
Mashup Score: 2Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Neoadjuvant immunotherapy for melanoma is now ready for clinical practice - Nature Medicine - 11 month(s) ago
Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
Source: NatureCategories: Latest Headlines, Oncologists1Tweet
FDA approves first perioperative immunotherapy regimen for resectable NSCLC. Based on KEYNOTE 671, #neoadjuvant pembrolizumab + chemotherapy followed by one year of adjuvant pembrolizumab now FDA approved for pts with resectable (T≥4 cm or N+) NSCLC. https://t.co/wsSIoJAJG4